{"id":"NCT00147316","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke","officialTitle":"Japan Alteplase Clinical Trial (J-ACT): Phase 3 Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Acute Ischemic Stroke Within 3 Hours of Onset","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-04","primaryCompletion":null,"completion":"2003-09","firstPosted":"2005-09-07","resultsPosted":"2012-02-24","lastUpdate":"2012-03-01"},"enrollment":103,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cerebral Infarction","Brain Ischemia"],"interventions":[{"type":"DRUG","name":"Alteplase","otherNames":[]}],"arms":[{"label":"Alteplase","type":"EXPERIMENTAL"}],"summary":"Based on previous studies comparing Duteplase\\[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase\\] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved dosage of 0.9mg/kg, aiming to assess the efficacy and safety of alteplase for the Japanese.","primaryOutcome":{"measure":"Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 at 3 Months","timeFrame":"at 3 months","effectByArm":[{"arm":"Alteplase","deltaMin":38,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["16763187","21737309"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":103},"commonTop":["Haemorrhagic cerebral infarction","Haemorrhage subcutaneous","Urinary tract infection NOS","Pyrexia","Headache NOS"]}}